Compare Clorox Co (CLX) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Clorox Co vs Summit Therapeutics Inc — how do they compare? Clorox Co trades at $108.39 (market cap $13.09B), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: Clorox Co and Summit Therapeutics Inc are close in size by market cap, and Clorox Co pays a 4.62% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| CLX | SMMT | |
|---|---|---|
Market Cap | $13.09B | $12.06B |
Sector | Consumer Staples | Health |
52-Week High | $127.16 | $26.98 |
52-Week Low | $86.12 | $12.55 |
Enterprise Value | $18.47B | $11.39B |
Dividend Yield | 4.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Clorox (CLX) trades at $105.69, down 1.87% on the day, with a mixed technical picture showing bullish moving averages but overbought RSI signals. Recent Q4 2026 earnings beat expectations with EPS of $1.66 versus $1.64 estimated, though revenue trends remain pressured by inflation and consumer value-seeking. The company increased its quarterly dividend to $1.25 per share, signaling confidence in cash flow stability.
Outlook is cautious amid margin pressures and competitive threats, with Wall Street largely neutral (69% hold rating). The consensus price target of $97.50 suggests limited upside from current levels, while debt-to-asset ratio rising to 66.4% in 2026 highlights balance sheet risks. Investment appeal hinges on successful cost management and category recovery.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Clorox Co
With a history dating back more than 100 years, Clorox now plays in a variety of categories across the consumer products space, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal-care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. Just shy of 85% of Clorox's sales stem from its home turf.
Read more on CLX →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
